Key terms
About ATHA
Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ATHA news
Mar 08
7:05am ET
Athira Pharma presents clinical, preclinical data of fosgonimeton
Feb 28
12:10am ET
Analysts Are Bullish on These Healthcare Stocks: Athira Pharma (ATHA), BeiGene (BGNE)
Feb 23
12:15am ET
Favorable Outlook for Athira Pharma with Strong Trial Progress and Robust Financials Prompting a ‘Buy’ Rating
Feb 22
6:55pm ET
Goldman Sachs Sticks to Their Hold Rating for Athira Pharma (ATHA)
Feb 22
4:26pm ET
Athira Pharma Launches New Equity Incentive Plan for Talent
Feb 22
4:20pm ET
Athira Pharma reports FY23 EPS ($3.09), consensus ($3.33)
Feb 15
11:56am ET
2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)
Feb 08
4:05pm ET
Athira Pharma publishes research highlighting ATH-1105
Jan 22
2:01pm ET
Analysts’ Top Healthcare Picks: Petros Pharmaceuticals (PTPI), Athira Pharma (ATHA)
Jan 11
1:58am ET
Athira Pharma: A Buy Rating Backed by Promising Alzheimer’s Drug Prospects and Strong Cash Position
Jan 08
7:45pm ET
Fosgonimeton’s Promise: A Buy Rating for Athira Pharma Amidst Positive Trial Outlook
Jan 08
3:49pm ET
Fly Insider: Athira Pharma, Microstrategy among week’s notable insider trades
Jan 08
7:58am ET
Athira Pharma provides 2024 clinical pipeline outlook
Jan 08
7:55am ET
Athira Pharma CMO Hans Moebius retires
Jan 07
5:27am ET
BTIG Reaffirms Their Buy Rating on Athira Pharma (ATHA)
Jan 05
12:50am ET
Analysts’ Top Healthcare Picks: Athira Pharma (ATHA), Syndax Pharmaceuticals (SNDX)
Jan 03
10:46am ET
Buy Rating Affirmed for Athira Pharma as LIFT-AD Trial Progresses with Promising Prospects and Solid Financial Standing
Jan 03
7:05am ET
Athira Pharma completes enrollment of Phase 2/3 LIFT-AD trial of fosgonimeton
Jan 02
9:09am ET
BTIG Keeps Their Buy Rating on Athira Pharma (ATHA)
Dec 31
5:07am ET
BTIG Sticks to Its Buy Rating for Athira Pharma (ATHA)
Dec 15
2:48am ET
Optimistic Outlook for Athira Pharma Despite Setback: Buy Rating Affirmed
Dec 12
7:40pm ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Bioxcel Therapeutics (BTAI) and Athira Pharma (ATHA)
Dec 12
5:25pm ET
Goldman Sachs Keeps Their Hold Rating on Athira Pharma (ATHA)
Dec 12
11:45am ET
Buy Rating for Athira Pharma Backed by Promising Fosgonimeton Trial Results and Favorable Safety Profile
Dec 12
7:06am ET
Athira Pharma announces results from exploratory Phase 2 trial of fosgonimeton
No recent news articles are available for ATHA
No recent press releases are available for ATHA
ATHA Financials
Key terms
Ad Feedback
ATHA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ATHA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range